PE20131064A1 - Preparacion de particulas recubiertas - Google Patents

Preparacion de particulas recubiertas

Info

Publication number
PE20131064A1
PE20131064A1 PE2013000025A PE2013000025A PE20131064A1 PE 20131064 A1 PE20131064 A1 PE 20131064A1 PE 2013000025 A PE2013000025 A PE 2013000025A PE 2013000025 A PE2013000025 A PE 2013000025A PE 20131064 A1 PE20131064 A1 PE 20131064A1
Authority
PE
Peru
Prior art keywords
preparation
coated particles
layer containing
coated
thiazolcarboxyl
Prior art date
Application number
PE2013000025A
Other languages
English (en)
Inventor
Kazuhiro Nakamura
Teppei Ogawa
Tomoya Akutagawa
Original Assignee
Teijin Pharma Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=45441336&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20131064(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Teijin Pharma Ltd filed Critical Teijin Pharma Ltd
Publication of PE20131064A1 publication Critical patent/PE20131064A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A61K9/2081—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets with microcapsules or coated microparticles according to A61K9/50
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5015—Organic compounds, e.g. fats, sugars
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Inorganic Chemistry (AREA)
  • Zoology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Organic Chemistry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

REFERIDA A UNA TABLETA DE DESINTEGRACION RAPIDA EN LA CAVIDAD ORAL QUE COMPRENDE PARTICULAS NUCLEARES DE ACIDO 2-(3-CIANO-4-ISOBUTILOXIFENIL)-4-METIL-5-TIAZOLCARBOXILICO RECUBIERTAS CON UNA CAPA QUE CONTIENE UN COPOLIMERO DE ACIDO METACRILICO Y SOBRECUBIERTAS CON UNA CAPA QUE CONTIENE AZUCARES SOLUBLES EN AGUA TAL COMO EL MANITOL. TAMBIEN COMPRENDE DESINTEGRANTES TAL COMO LA CROSPOVIDONA
PE2013000025A 2010-07-09 2011-07-08 Preparacion de particulas recubiertas PE20131064A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2010156874 2010-07-09

Publications (1)

Publication Number Publication Date
PE20131064A1 true PE20131064A1 (es) 2013-09-23

Family

ID=45441336

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2013000025A PE20131064A1 (es) 2010-07-09 2011-07-08 Preparacion de particulas recubiertas

Country Status (24)

Country Link
US (1) US20130101670A1 (es)
EP (1) EP2591781B1 (es)
JP (1) JP5000017B2 (es)
KR (1) KR20130113348A (es)
CN (1) CN102958522B (es)
AR (1) AR082139A1 (es)
AU (1) AU2011274851A1 (es)
BR (1) BR112013000298A2 (es)
CA (1) CA2804874C (es)
CL (1) CL2013000089A1 (es)
CO (1) CO6650363A2 (es)
EC (1) ECSP12012360A (es)
ES (1) ES2644064T3 (es)
MA (1) MA34460B1 (es)
MX (1) MX2013000282A (es)
NZ (1) NZ605562A (es)
PE (1) PE20131064A1 (es)
PH (1) PH12013500032A1 (es)
RU (1) RU2013105456A (es)
TN (1) TN2012000623A1 (es)
TW (1) TW201217001A (es)
UY (1) UY33499A (es)
WO (1) WO2012005365A1 (es)
ZA (1) ZA201300106B (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9248119B2 (en) 2010-06-16 2016-02-02 Takeda Pharmaceuticals U.S.A., Inc. Modified release dosage forms of xanthine oxidoreductase inhibitor or xanthine oxidase inhibitors
ES2532210T3 (es) 2010-09-10 2015-03-25 Takeda Pharmaceuticals U.S.A., Inc. Métodos para el tratamiento concomitante de teofilina y febuxostat
CN106267220B (zh) * 2015-05-14 2019-06-28 北京科信必成医药科技发展有限公司 愈创甘油醚氢溴酸右美沙芬无水吞服掩味制剂
JP7108384B2 (ja) * 2016-07-13 2022-07-28 日本ケミファ株式会社 ２－［３－シアノ－４－（２－メチルプロポキシ）フェニル］－４－メチルチアゾール－５－カルボン酸の口腔内崩壊錠
GB202001237D0 (en) * 2020-01-29 2020-03-11 Sisteks D O O Granular pharmaceutical product for oral administration from a pre-filled straw and method of manufacturing such pharmaceutical product

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100554924B1 (ko) * 1998-05-18 2006-03-03 다케다 야쿠힌 고교 가부시키가이샤 구강내 붕괴 정제
JP4300652B2 (ja) 1998-09-21 2009-07-22 大正製薬株式会社 経口用固形製剤
JP3389205B2 (ja) 1999-06-29 2003-03-24 武田薬品工業株式会社 口腔内速崩壊錠
KR20050044545A (ko) * 2001-11-21 2005-05-12 에자이 가부시키가이샤 산에 불안정한 생리활성 화합물을 함유하는 제제 조성물및 그 제법
JP2005023058A (ja) 2003-06-10 2005-01-27 Lion Corp 咀嚼型医薬製剤用薬物粒子及びその製造方法、並びに薬物粒子を含有する咀嚼型医薬固形製剤及びその製造方法
JP5062872B2 (ja) 2003-08-13 2012-10-31 東和薬品株式会社 不快な味を低減した口腔内崩壊錠剤
US20090155361A1 (en) * 2005-08-18 2009-06-18 Masahiko Narasaki Tablet with multiple drug-containing sections
PE20070698A1 (es) * 2005-11-14 2007-08-17 Teijin Pharma Ltd Comprimido de disgregacion rapida intraoral que contiene hidrocloruro de ambroxol
JP5123517B2 (ja) * 2005-11-14 2013-01-23 帝人ファーマ株式会社 アンブロキソール口腔内速崩性錠剤
JP2008050324A (ja) * 2006-08-28 2008-03-06 Ohara Yakuhin Kogyo Kk 苦味遮蔽組成物。
JP5097488B2 (ja) 2006-09-13 2012-12-12 京都薬品工業株式会社 苦味マスキング
US9248119B2 (en) * 2010-06-16 2016-02-02 Takeda Pharmaceuticals U.S.A., Inc. Modified release dosage forms of xanthine oxidoreductase inhibitor or xanthine oxidase inhibitors

Also Published As

Publication number Publication date
JPWO2012005365A1 (ja) 2013-09-05
CN102958522A (zh) 2013-03-06
ZA201300106B (en) 2013-09-25
MX2013000282A (es) 2013-02-11
RU2013105456A (ru) 2014-08-20
NZ605562A (en) 2013-11-29
UY33499A (es) 2012-01-31
MA34460B1 (fr) 2013-08-01
ES2644064T3 (es) 2017-11-27
PH12013500032A1 (en) 2013-02-11
KR20130113348A (ko) 2013-10-15
EP2591781A1 (en) 2013-05-15
CA2804874C (en) 2019-07-23
CO6650363A2 (es) 2013-04-15
CA2804874A1 (en) 2012-01-12
WO2012005365A1 (ja) 2012-01-12
TW201217001A (en) 2012-05-01
BR112013000298A2 (pt) 2016-05-31
EP2591781A4 (en) 2014-12-03
CL2013000089A1 (es) 2013-03-08
CN102958522B (zh) 2015-12-16
TN2012000623A1 (en) 2014-04-01
ECSP12012360A (es) 2013-02-28
US20130101670A1 (en) 2013-04-25
AR082139A1 (es) 2012-11-14
JP5000017B2 (ja) 2012-08-15
AU2011274851A1 (en) 2013-01-31
EP2591781B1 (en) 2017-09-27

Similar Documents

Publication Publication Date Title
HUS1900017I1 (hu) Gyûrûs boronsavészter-származékok és terápiás alkalmazásuk
IL272501A (en) Oral administration forms of bendamustine and their medical use
CL2012003393A1 (es) Combinacion farmaceutica que comprende una insulina de accion prolongada y un inhibidor de la dpp-4, que es preferiblemente linagliptina; insulina basal de accion prolonagada seleccionada de insulina detemir, glargina y degludec; inhibidor de la dpp-4 preferiblemente linagliptina; y composición farmaceutica.
CL2014002754A1 (es) Forma de dosis de liberación controlada solida que comprende un nucleo con una primera porcion de un analgesico opioide y una cubierta que encierra el nucleo y comprende una segunda porcion del analgesico opioide; metodo de preparacion; uso en el tratamiento del dolor. (divisional de solicitud n°1450-2014).
IL226448A (en) A m72 antigen-containing immunosuppressant drug and its uses for drug preparation
CR20150402A (es) Formulaciones farmacéuticas resistentes a la manipulación indebida
EP2743271A4 (en) PIM KINASEHEMMER, MANUFACTURING METHOD AND ITS USE IN THE MANUFACTURE OF MEDICAMENTS
MX392839B (es) Liberacion autorregulada de ingrediente farmaceutico activo.
PL3363433T3 (pl) Sposoby zmniejszania ryzyka zdarzenia sercowo-naczyniowego u osobnika na terapii statynami z zastosowaniem estru etylowego kwasu eikozapentaenowego
MX391480B (es) Formulaciones farmaceuticas que comprenden pilocarpina.
BRPI1009411A2 (pt) preparação externa contendo um agente analgésico/antiinflamatório
MX2013007677A (es) Inhibidores macrociclicos de serina proteasa de hepatitis.
MX2011011109A (es) Formulaciones orales de bendamustina.
MX347101B (es) Forma de dosis de disolucion rapida de vacuna oral que usa almidon.
PL2585041T3 (pl) Preparat farmaceutyczny o zamaskowanym smaku o przyspieszonym początku działania
WO2014114255A3 (zh) 一种定位速释生物粘附剂及应用
EP2687539A4 (en) ANNEXIN V VERSION, ITS MANUFACTURE AND USE
EA201400737A1 (ru) Система доставки на основе множества пеллет с немедленным высвобождением активного вещества
ZA201208605B (en) Stable ready to use injectable paracetamol formulation
CO6592109A2 (es) Nueva forma cristalina de un derivado de ciclopropilbenzamida
MX2015010486A (es) Composicion masticable para administracion oral y proceso para preparar la misma.
PE20142460A1 (es) Composiciones farmaceuticas orales estables de liberacion inmediata que contienen prasugrel
AR082139A1 (es) Preparacion recubiertas con particulas finas
WO2012023024A3 (en) Controlled release formulations of dronedarone
GB2495651B (en) A novel herbal formulation advocated for the prevention and management of coronary heart disease

Legal Events

Date Code Title Description
FD Application declared void or lapsed